ondasdechoque.org
PT-BR

Shoulder calcification type and shockwave outcomes · Comparison study · 2019

Does the type of shoulder calcium deposit affect shockwave results?

In this study, everyone had one high-energy shockwave session. A year later, pain had eased in all three groups, most in people whose deposits looked less dense on X-ray: 14 of 20 improved by more than 80%, compared with 5 of 20 with dense deposits and 3 of 20 with no deposit.

Improved over time; best with less dense deposits
people with long-lasting shoulder tendon pain
60
high-energy shockwave session
1
months of follow-up
12

Good to know: No group went without shockwave.

Wu KT, Chou WY, Wang CJ, et al. Biomed Res Int, 2019 · Read the paper ↗

How this study worked

No calciumdeposit20 peopleLess densedeposit20 peopleDense deposit20 people
Groups were compared, but people were not assigned to them by lot. Each dot is one person.

What happened

Shoulder pain by deposit type

0–10 pain scale · start and after 12 months

StartAfter 12 months

Pain eased in all three groups. It fell most with less dense deposits, from about 5 to 1.5, compared with about 3 with no deposit and about 4 with dense deposits.
Show the numbers
GroupPeopleStartAfter 12 months
No calcium deposit205.52.9
Less dense deposit205.41.5
Dense deposit205.43.8

The treatment

No calcium deposit

Focused, 1 session

Focused wavesMeet at a focal zone below the skin
Sessions
1
Pulses
3,000 per session
Strength
0.32mJ/mm²
Numbing
None
Device
Ossatron or Orthospec

Less dense deposit

Focused, 1 session

Focused wavesMeet at a focal zone below the skin
Sessions
1
Pulses
3,000 per session
Strength
0.32mJ/mm²
Numbing
None
Device
Ossatron or Orthospec

Dense deposit

Focused, 1 session

Focused wavesMeet at a focal zone below the skin
Sessions
1
Pulses
3,000 per session
Strength
0.32mJ/mm²
Numbing
None
Device
Ossatron or Orthospec

Compared with: No untreated group; the three groups differed only in the type of deposit

Settings are what each study used, not a prescription.

Who took part

60 people with shoulder tendon pain for over 6 months despite at least 3 months of other care: 20 with no deposit, 20 with less dense and 20 with dense deposits.

No calcium deposit20 people
Less dense deposit20 people
Dense deposit20 people

Side effects

The study does not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Shoulder tendinosis symptomatic >6 months despite ≥3 months conservative care. Full-thickness tears and type II/III acromia were excluded. Groups: noncalcific NCTS, dense type I DCTS and translucent type II/III TCTS. DCTS symptom duration remained longer after matching (20.3 vs 9.8 months for TCTS).

Noncalcific20enrolled

Source reports this participant group.

Type II/III20enrolled

Source reports this participant group.

Type I20enrolled

Source reports this participant group.

Pain VAS1 reported outcome
01
Twelve months

Pain VAS

Pain VAS points

means
GroupnBaselineFollow-up
Noncalcific205.5 (SD 0.76)2.9 (SD 2.86)
Type II/III205.4 (SD 1.04)1.5 (SD 2.48)
Type I205.4 (SD 0.94)3.8 (SD 2.46)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.011

Across three morphology groups

Kruskal-Wallis

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

Constant-Murley total1 reported outcome
02
Twelve months

Constant-Murley total

Constant-Murley total points

BaselineFollow-up
Noncalcific
78.7
Type II/III
86.9
Type I
71.1
0100 points
means
GroupnBaselineFollow-up
Noncalcific2052.5 (SD 14.5)78.7 (SD 18.3)
Type II/III2049.7 (SD 9.03)86.9 (SD 19.7)
Type I2053.8 (SD 7.66)71.1 (SD 17.8)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

CMS pain subscore1 reported outcome
03
Twelve months

CMS pain subscore

CMS pain subscore points

means
GroupnBaselineFollow-up
Noncalcific204.6 (SD 0.88)7.7 (SD 2.13)
Type II/III204.1 (SD 1)8.8 (SD 2)
Type I204.6 (SD 0.6)6.5 (SD 2.16)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

CMS night pain1 reported outcome
04
Twelve months

CMS night pain

CMS night pain points

means
GroupnBaselineFollow-up
Noncalcific202.6 (SD 0.83)4.2 (SD 1.04)
Type II/III202.6 (SD 0.94)4.3 (SD 1.13)
Type I202.6 (SD 0.5)3.3 (SD 1.2)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

CMS strength1 reported outcome
05
Twelve months

CMS strength

CMS strength points

means
GroupnBaselineFollow-up
Noncalcific2012.6 (SD 3.66)19.2 (SD 5.22)
Type II/III2011.2 (SD 3.23)22.4 (SD 5.1)
Type I2012.7 (SD 3.08)18.4 (SD 4.69)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

CMS activity1 reported outcome
06
Twelve months

CMS activity

CMS activity points

means
GroupnBaselineFollow-up
Noncalcific2010.8 (SD 3.16)16.1 (SD 4.16)
Type II/III2010 (SD 2.51)17.6 (SD 4.24)
Type I2010.7 (SD 2.56)14.7 (SD 4.13)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

CMS motion1 reported outcome
07
Twelve months

CMS motion

CMS motion points

means
GroupnBaselineFollow-up
Noncalcific2022 (SD 8.41)31.7 (SD 7.18)
Type II/III2021.9 (SD 7.99)33.9 (SD 7.77)
Type I2023.3 (SD 5.2)28.3 (SD 7.06)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

Complaint-free1 reported outcome
08
Twelve months

Complaint-free

people

Noncalcific3 / 20
Type II/III14 / 20
Type I5 / 20

Improvement >80%, not necessarily zero symptoms.

Analysis details and source

Descriptive source-reported counts; no effect estimate reconstructed.

How treatment was delivered
Single-session regimen

One high-energy electrohydraulic treatment with Ossatron or Orthospec, 3,000 impulses at 0.32 mJ/mm², without anesthesia/analgesics. Image-guided deposit targeting or maximum tenderness for noncalcific disease; supine/sitting.

HARMS & TOLERABILITY

No structured adverse-event results are provided. The lack of a safety table cannot establish absence of harms.

LIMITS OF THE ANALYSIS

Small retrospective matched subset, no sham, residual duration imbalance and incomplete imaging follow-up. Table 2 versus text p-values conflict: CMS .007/.014, pain subscore .004/.008, strength .002/.004. Table 1 TCTS age SD 93.58 and Table 2 activity range exceeding specified maximum are source errors requiring clarification. No conflicts declared; biostatistics support acknowledged.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Small retrospective matched subset, no sham, residual duration imbalance and incomplete imaging follow-up. Table 2 versus text p-values conflict: CMS .007/.014, pain subscore .004/.008, strength .002/.004. Table 1 TCTS age SD 93.58 and Table 2 activity range exceeding specified maximum are source errors requiring clarification. No conflicts declared; biostatistics support acknowledged.
Research review

Source-linked critical reading

nonrandom comparative

Reading depthMaterial consulted
Technical source record

Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. The paper cites no supplementary material.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Retrospective propensity-matched comparison: 60 of 291 treated patients from 1998–2015, 20 per morphology group. All received ESWT; matching was on age, sex, baseline pain and function, not randomized treatment.

Participants and setting

Shoulder tendinosis symptomatic >6 months despite ≥3 months conservative care. Full-thickness tears and type II/III acromia were excluded. Groups: noncalcific NCTS, dense type I DCTS and translucent type II/III TCTS. DCTS symptom duration remained longer after matching (20.3 vs 9.8 months for TCTS).

Treatment

One high-energy electrohydraulic treatment with Ossatron or Orthospec, 3,000 impulses at 0.32 mJ/mm², without anesthesia/analgesics. Image-guided deposit targeting or maximum tenderness for noncalcific disease; supine/sitting.

Comparison

Morphology groups received the same intervention. NSAIDs, aspirin and physiotherapy were stopped 2 weeks before and 4 weeks after. No untreated or sham comparison.

Outcomes and timing

VAS and Constant-Murley total/subscores before and 3, 6 and 12 months; primary extracted comparison at 12 months. Satisfaction categories used >80%, 50–79%, 25–49% and <24% symptom improvement.

What the results show

At 12 months VAS NCTS/TCTS/DCTS=2.9/1.5/3.8; CMS=78.7/86.9/71.1. Complaint-free counts 3/20, 14/20, 5/20. Night-pain and activity scores were similar between NCTS and TCTS, both better than DCTS. Results suggest morphology-associated prognosis, not proof of treatment efficacy.

Harms

No structured adverse-event results are provided. The lack of a safety table cannot establish absence of harms.

Limits and disclosures

Small retrospective matched subset, no sham, residual duration imbalance and incomplete imaging follow-up. Table 2 versus text p-values conflict: CMS .007/.014, pain subscore .004/.008, strength .002/.004. Table 1 TCTS age SD 93.58 and Table 2 activity range exceeding specified maximum are source errors requiring clarification. No conflicts declared; biostatistics support acknowledged.

Application to care

For refractory shoulder symptoms, calcification morphology may inform prognosis. Natural resorption of type II/III deposits and unmeasured factors prevent assigning the observed advantage to ESWT alone.

What remains to be tested

A morphology-stratified sham-controlled trial with prospective imaging and validated outcome reporting is needed; reconcile the table/text inconsistencies first.

THE ORIGINAL SOURCE

Read the original article.

Efficacy of Extracorporeal Shockwave Therapy on Calcified and Noncalcified Shoulder Tendinosis: A Propensity Score Matched Analysis

Wu KT, Chou WY, Wang CJ, Chen CY, Ko JY, Chen PC, Cheng JH, Yang YJ. · Biomed Res Int · 2019

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →